Karyopharm Therapeutics Inc. (KPTIQ) revenue by segment
KPTIQOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTI
Share price
Not available yet
Price, market cap and P/E appear here once daily prices are connected.
Karyopharm Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $114.86M | $112.81M | $112.01M | $120.45M | $98.44M | $76.21M | $30.54M | $0 | – | 78.6% | +1.8% |
| License and Other | $31.21M | $32.43M | $34.02M | $36.63M | $111.38M | $31.88M | $10.35M | $30.34M | $1.61M | 21.4% | -3.8% |
By region
From the segment and revenue-disaggregation notes of Karyopharm Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes. The KPIs tab shows these segments next to Karyopharm Therapeutics's operating metrics, with full history, charts and a link to each filing.
See a number that looks wrong?